The Bacterium That Talks to Our Cells

1. A Bacterium With Tiny Grappling Hooks

The intestine is hardly a still environment. Food, fluids, and mucus are constantly moving. LGG has specialized structures that help it interact with this shifting landscape: SpaCBA pili.

These hair-like protein filaments can bind to components of intestinal mucus. A protein called SpaC plays a particularly important role in adhesion. Think of the pili as molecular grappling hooks that help LGG maintain contact with the mucus layer. [1, 2]

That layer is far more than a slippery coating. It forms a crucial interface between intestinal contents, resident microbes, and the cells lining our gut.

Yet the ability to attach does not mean LGG permanently colonizes the intestine. After supplementation stops, the strain often becomes undetectable.

Does a bacterium really need to stay in our gut to make a difference?

2. LGG’s Secret Messages

Here is where the science becomes especially intriguing. LGG can release proteins into its surroundings. Two of them are known as p40 and p75.

Researchers have investigated p40 in particular. In cell and animal models, it can initiate a signaling cascade usually regulated by the body's own growth factors. At the center is the epidermal growth factor receptor (EGFR), a cell-surface receptor involved in processes including cell survival and repair.

The sequence is remarkably precise: p40 can act through the enzyme ADAM17 to promote the release of the body's own signaling molecule HB-EGF. HB-EGF then activates EGFR and downstream pathways, including PI3K/Akt. [3]

In experimental models, this signaling may support processes that help intestinal epithelial cells survive and maintain barrier function.

The bacterium sends a signal. The human cell carries out its own protective program.

Whether this particular pathway explains the clinical effects of orally administered LGG has not yet been established.

3. The Gut Barrier: A Living Boundary

We often picture the intestinal barrier as a wall. In reality, it is a dynamic system. Its cells renew themselves, absorb nutrients, and communicate with immune cells. Between neighboring cells, structures called tight junctions help regulate what can pass through the spaces between them.

Research on p40 shows that microbial proteins can influence epithelial protective processes in experimental models. This is not clinical proof that LGG repairs a damaged intestinal barrier in humans. It does, however, reveal how specific communication between a microbe and its host can be. [3]

4. A Bacterium That May Help Other Bacteria

LGG does not live in isolation. The intestine is an ecosystem in which microbes share nutrients, compete for resources, and transform one another's metabolic products.

One especially intriguing possibility involves butyrate-producing bacteria. Butyrate is a short-chain fatty acid produced in the colon when microbes ferment carbohydrates we cannot digest ourselves. It is an important energy source for colon cells and also influences metabolic and immune processes.

Butyrate producers include certain members of Roseburia, Anaerostipes, Eubacterium, and Faecalibacterium. LGG itself is not a typical butyrate producer.

The Principle of Cross-Feeding

When LGG ferments carbohydrates, it can produce lactate, among other metabolites. Certain other bacteria can use lactate (often together with acetate) as a starting material for producing butyrate.

This cooperation is called cross-feeding: a substance released by one microorganism becomes a resource for another.

An ex vivo experiment using intestinal microbial communities from six adults provides a more direct clue. In a model containing tributyrin, adding LGG increased measured butyrate and favored Coprococcus catus, a lactate-utilizing butyrate producer. The authors proposed lactate-mediated cross-feeding. But tributyrin itself releases butyrate, the work was conducted outside the body, and the proposed lactate pathway was not conclusively proven. This does not establish that ordinary LGG supplementation increases butyrate in humans. [7]

Cooperation can also run the other way. In a co-culture experiment, the butyrate producer Anaerostipes hadrus broke down certain fructooligosaccharides, releasing products that LGG could use for growth. [8]

Whether LGG increases butyrate production through cross-feeding in the living human gut remains unknown.

What Have Researchers Observed in Humans?

A small study of infants with cow's milk allergy examined a specialized extensively hydrolyzed formula with or without LGG. Researchers reported changes in the intestinal microbiota in the LGG group, including bacterial groups containing butyrate-producing members. They also observed associations involving stool butyrate levels, particular bacteria, and the development of tolerance to cow's milk. [4]

The study was small and involved a specific patient population. It does not prove that LGG reliably raises butyrate levels in healthy adults, or that butyrate caused the observed development of immune tolerance.

Still, it points toward a remarkable possibility: one way a gut bacterium may matter is by supporting what other microbes can do.

5. Tiny Parcels Carrying Information

Bacteria can release small, membrane-enclosed particles called extracellular vesicles. These particles can carry proteins and other biological molecules. There is now specific experimental evidence for LGG-derived vesicles. A 2024 study investigated them in skin and endothelial cells and in a mouse model of wound healing, reporting effects on cell migration and angiogenesis and exploring the role of miR-21-5p. These are wound-healing findings, not evidence of a clinical effect on the human intestinal barrier. [9]

An especially intriguing 2019 study found communication in the opposite direction: extracellular vesicles released by intestinal epithelial cells increased LGG's production of p40 in experimental cell and mouse models. The host may influence the microbe's messages, too. [10]

That raises another question: can bacteria deliver biological signals without making direct contact with a host cell? For LGG, this research remains largely experimental. A clinical benefit of these vesicles in humans has not been demonstrated.

6. What Can LGG Actually Do in Humans?

LGG has been studied in numerous clinical trials. One of its better-supported applications is preventing antibiotic-associated diarrhea in children. Randomized trials and meta-analyses suggest a benefit in this setting, although results depend on the population, dose, and study conditions. [5]

The picture is less clear for treating an acute gastrointestinal infection once it has begun. Some pooled analyses of older studies suggest a modest reduction in diarrhea duration, but a large, rigorous US trial in children found no corresponding benefit. [6]

That does not contradict the molecular research. A bacterium's ability to send signals does not guarantee a measurable health benefit in every clinical situation.

Clinical studies ask whether LGG helps in a particular setting. Mechanistic studies explore how it might work. The direct link between those two levels is still not fully understood.

7. Why These Discoveries Change How We Think About Probiotics

For years, the prevailing image of a helpful probiotic was a bacterium that settles in the intestine and crowds out unwanted microbes. LGG shows why that picture is incomplete.

Even during a temporary stay, a bacterial strain may interact with mucus, release signaling molecules, and potentially influence microbial metabolic networks.

And the specific strain matters. Not every bacterium belonging to Lacticaseibacillus rhamnosus necessarily shares the characteristics of LGG (ATCC 53103).

LGG's story reminds us that our relationship with the microbiome is more than organisms simply living side by side. It is a continual exchange of substances and signals.